Allergen specific immunotherapy, together with drugs and allergen avoidance, is a cornerstone in the management of respiratory allergy. The traditional subcutaneous route is burdened with the risk of severe adverse events; therefore, safer routes of administration (noninjection or local routes) have been investigated and developed. Controlled trials failed to demonstrate the clinical efficacy a...

BACKGROUND Grass pollen immunotherapy for allergic rhinitis is a disease-modifying treatment that results in long-term clinical tolerance lasting years after treatment discontinuation. Active treatment is associated with generation of inhibitory grass pollen-specific IgG antibodies capable of blocking allergen-IgE interactions. OBJECTIVES We sought to investigate the involvement of IgG-associ...

few biomarkers that can predict the clinical response to allergen immunotherapy (ait) have been identified. the aim of the present study was to investigate parameters that could be used “in predicting the clinical response to ait” in children with asthma caused by house dust mites. we evaluated 107 children with mild persistent asthma who were sensitised only to mite aeroallergens. the study gr...

BACKGROUND The great majority (60-80 %) of patients consulting specialist physicians for allergic respiratory disease are polysensitized and thus may be potentially clinically polyallergic. However, management approaches to allergen immunotherapy (AIT) in polysensitized and polyallergic patients are not standardized. METHODS An international group of clinicians with in-depth expertise in AIT ...

The initial dose should be administered under the supervision of a physician because anaphylaxis and laryngopharyngeal edema have occurred in rare cases.1 The manufacturer suggests that timothy grass pollen allergen extract be avoided in patients taking beta blockers, alpha blockers, ergot alkaloids, tricyclic antidepressants, levothyroxine, monoamine oxidase inhibitors, chlorpheniramine, diphe...

Background Allergen-specific immunotherapy (SIT) is the only specific, disease-modifying treatment for allergy and may have long-lasting effects. It is given traditionally in the form of multiple subcutaneous injections which makes the treatment inconvenient. Furthermore, systemic allergenadministration may cause severe side effects. Therefor the development of alternative routes for SIT has be...

BACKGROUND Allergen-specific immunotherapy (SIT) can significantly improve symptoms and reduce the need for symptomatic medication. OBJECTIVE The aim of this study was to investigate changes in skin reactivity to house dust mites (HDMs) as an immunologic response and associated factors after 1 year of immunotherapy. METHODS A total of 80 patients with allergic airway diseases who received s...

Most Latin-American countries use subcutaneous immunotherapy (SCIT) extracts from the United States and Europe and sublingual immunotherapy (SLIT) from Europe, with the exception of Argentina, Brazil, Cuba and Mexico. The number of researches on immunotherapy (IT) in Latin America has increased extensively in the last years. Only few Latin American countries have their own guidelines on IT, and...

OBJECTIVE Allergic rhinitis (AR) is a disease with high and increasing prevalence. The management of AR includes allergen avoidance, anti-allergic drugs, and allergen specific immunotherapy (AIT), but only the latter works on the causes of allergy and, due to its mechanisms of action, modifies the natural history of the disease. Sublingual immunotherapy (SLIT) was proposed in the 1990s as an op...